Baidu
map

肝细胞癌患者行放射性栓塞比化学栓塞病情进展减慢且能减轻毒性反应

2011-06-07 Salem R,et al. MedSci原创

背景与目的:化学栓塞是肝细胞癌(HCC)的标准治疗方案。(90)Y玻璃微球放射性栓塞是一种新的治疗方法,经动脉进行放射治疗。我们比较分析了这两种肝细胞癌治疗方法的疗效。 方法:收集463例经动脉行局部治疗(化学栓塞或放射性栓塞)9年以上的患者数据。排除了不适合进行比较和分析的245例患者(122例为接受化学治疗患者,123例为放射性治疗患者)的数据。随访患者的毒性症状,均进行基线图像分析并按时间

背景与目的:化学栓塞是肝细胞癌(HCC)的标准治疗方案。(90)Y玻璃微球放射性栓塞是一种新的治疗方法,经动脉进行放射治疗。我们比较分析了这两种肝细胞癌治疗方法的疗效。 方法:收集463例经动脉行局部治疗(化学栓塞或放射性栓塞)9年以上的患者数据。排除了不适合进行比较和分析的245例患者(122例为接受化学治疗患者,123例为放射性治疗患者)的数据。随访患者的毒性症状,均进行基线图像分析并按时间点随访。总存活率为主要测量结果。次要测量结果为安全性、应答率及病情进展时间。采用单变量及多元分析。 结果:化学栓塞组较多出现腹痛及转氨酶增高(P<.05)。具有放射性栓塞组的应答率高于化学栓塞组的趋势(49%:36%, P=0.104)。尽管放射性栓塞治疗比化学栓塞病情进展时间延长(13.3个月:8.4 个月, P=0.046),而中位生存期差异无统计学意义(17.4个月:20.5个月, P=0.232)。癌症中期患者的生存率两组相似(P=0.42),化学栓塞组为17.5个月,放射性栓塞组为17.2个月。 结论:肝细胞癌患者采用化学栓塞或(90)Y玻璃微球放射性栓塞治疗其生存时间相似。与化

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1863176, encodeId=2a2f18631e6cc, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Jul 07 07:21:00 CST 2011, time=2011-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978297, encodeId=ea0019e8297ec, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Mar 29 16:21:00 CST 2012, time=2012-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2686, encodeId=16152686be, content=很新的的治疗方式,读后有一些疑问,为什么选取的HCC患者接受化疗或放疗均超过9年,患者的HCC分型及分化程度是否具有一致性,资料中未见解释,希望能提供原文学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=89bd33169, createdName=zhulaowu, createdTime=Tue Aug 09 18:12:00 CST 2011, time=2011-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764936, encodeId=8e521e649363b, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1dc37824931, createdName=ms7524819409032184, createdTime=Thu Jan 12 19:21:00 CST 2012, time=2012-01-12, status=1, ipAttribution=)]
    2011-07-07 xjy02
  2. [GetPortalCommentsPageByObjectIdResponse(id=1863176, encodeId=2a2f18631e6cc, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Jul 07 07:21:00 CST 2011, time=2011-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978297, encodeId=ea0019e8297ec, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Mar 29 16:21:00 CST 2012, time=2012-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2686, encodeId=16152686be, content=很新的的治疗方式,读后有一些疑问,为什么选取的HCC患者接受化疗或放疗均超过9年,患者的HCC分型及分化程度是否具有一致性,资料中未见解释,希望能提供原文学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=89bd33169, createdName=zhulaowu, createdTime=Tue Aug 09 18:12:00 CST 2011, time=2011-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764936, encodeId=8e521e649363b, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1dc37824931, createdName=ms7524819409032184, createdTime=Thu Jan 12 19:21:00 CST 2012, time=2012-01-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1863176, encodeId=2a2f18631e6cc, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Jul 07 07:21:00 CST 2011, time=2011-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978297, encodeId=ea0019e8297ec, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Mar 29 16:21:00 CST 2012, time=2012-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2686, encodeId=16152686be, content=很新的的治疗方式,读后有一些疑问,为什么选取的HCC患者接受化疗或放疗均超过9年,患者的HCC分型及分化程度是否具有一致性,资料中未见解释,希望能提供原文学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=89bd33169, createdName=zhulaowu, createdTime=Tue Aug 09 18:12:00 CST 2011, time=2011-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764936, encodeId=8e521e649363b, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1dc37824931, createdName=ms7524819409032184, createdTime=Thu Jan 12 19:21:00 CST 2012, time=2012-01-12, status=1, ipAttribution=)]
    2011-08-09 zhulaowu

    很新的的治疗方式,读后有一些疑问,为什么选取的HCC患者接受化疗或放疗均超过9年,患者的HCC分型及分化程度是否具有一致性,资料中未见解释,希望能提供原文学习。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1863176, encodeId=2a2f18631e6cc, content=<a href='/topic/show?id=c0b68135561' target=_blank style='color:#2F92EE;'>#肝细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81355, encryptionId=c0b68135561, topicName=肝细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Thu Jul 07 07:21:00 CST 2011, time=2011-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978297, encodeId=ea0019e8297ec, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Thu Mar 29 16:21:00 CST 2012, time=2012-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2686, encodeId=16152686be, content=很新的的治疗方式,读后有一些疑问,为什么选取的HCC患者接受化疗或放疗均超过9年,患者的HCC分型及分化程度是否具有一致性,资料中未见解释,希望能提供原文学习。, beContent=null, objectType=article, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=89bd33169, createdName=zhulaowu, createdTime=Tue Aug 09 18:12:00 CST 2011, time=2011-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1764936, encodeId=8e521e649363b, content=<a href='/topic/show?id=df00e086653' target=_blank style='color:#2F92EE;'>#病情#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70866, encryptionId=df00e086653, topicName=病情)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1dc37824931, createdName=ms7524819409032184, createdTime=Thu Jan 12 19:21:00 CST 2012, time=2012-01-12, status=1, ipAttribution=)]
Baidu
map
Baidu
map
Baidu
map